TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8312045

Group type: EXPERIMENTAL
Intervention: Letter from general practitioner suggesting reduction in benzodiazepine use.
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Letter from general practitioner plus four information sheets at monthly intervals.
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 209
Study: 2455011

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy (group I)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemotherapy alone (group II)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemotherapy (2 cycles)
Number of subjects: 96
Study: 31282292

Group type: EXPERIMENTAL
Intervention: Upper-extremity power-training intervention (3 times per week for 6 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest-training (RT) group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Training-rest group
Number of subjects: 12
Study: 29421165

Group type: EXPERIMENTAL
Intervention: Meditation group classes (Power of Breath, Sacred Sounds, Movement & Breath)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Meditation group classes
Number of subjects: 142
Study: 28838898

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 26652592

Group type: EXPERIMENTAL
Intervention: Unexplained chronic widespread pain
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Unexplained chronic fatigue
Number of subjects: 990

Group type: COMPARATOR
Intervention: Common associated factors for both conditions
Number of subjects: 990

Group type: COMPARATOR
Intervention: Education and medical illnesses
Number of subjects: 990

Group type: COMPARATOR
Intervention: Recent illness in a close relative, neuroticism, depression, and anxiety scores
Number of subjects: 990

Group type: COMPARATOR
Intervention: Concurrent anxiety and/or depression
Number of subjects: 990
Study: 23422921

Group type: EXPERIMENTAL
Intervention: Oat or barley products providing 0.3-12.1 g β-glucan
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Processed foods containing 4 g of β-glucan
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intact grains
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Processed foods
Number of subjects: 34
Study: 21402653

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (25 minutes)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Resting control condition (reading for 25 minutes)
Number of subjects: 64
Study: 19447268

Group type: EXPERIMENTAL
Intervention: Collaborative testing (experimental group)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Solo testing (control group)
Number of subjects: 89
Study: 16493102

Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stent
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Paclitaxel‐eluting stent
Number of subjects: 1386
Study: 12935409

Group type: EXPERIMENTAL
Intervention: Thoracic epidural blockade (TEB) with 0.5% lidocaine 3-5 ml every 2-4 hours for four weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (routine medicine only)
Number of subjects: 30
Study: 16422030

Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rifaximin and Placebo
Number of subjects: 14
Study: 9187286

Group type: EXPERIMENTAL
Intervention: Obstacle present
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pure level changes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Obstructed level changes
Number of subjects: 6
Study: 8444683

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3940792

Group type: EXPERIMENTAL
Intervention: Inhaled atropine sulfate (0.075 mg/kg)
Number of subjects: 18
Study: 30392186

Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 3725
Study: 26645117

Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (T.C. PTNS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Extended release oxybutynin (E.R.O.)
Number of subjects: 70
Study: 25463664

Group type: EXPERIMENTAL
Intervention: SRP + a single episode of aPDT
Number of subjects: 20

Group type: COMPARATOR
Intervention: SRP (Control Group)
Number of subjects: 20
Study: 22999673

Group type: EXPERIMENTAL
Intervention: Orthodontic force of 0.980 N applied for 3 hours, 15 hours, 3 days, 12 days, or 21 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (contralateral teeth without orthodontic appliances)
Number of subjects: 64
Study: 20116700

Group type: EXPERIMENTAL
Intervention: Primary closure (group I)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Secondary closure (group II)
Number of subjects: 93
Study: 17640058

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study: 15649652

Group type: EXPERIMENTAL
Intervention: 450 ml of black tea (acute)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 900 ml of black tea per day (chronic)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 66
Study: 16259812

Group type: EXPERIMENTAL
Intervention: 50 microg oestradiol patches (Evorel) used during the pill-free interval for two cycles
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo used during the pill-free interval for two cycles
Number of subjects: 14
Study: 9558519

Group type: EXPERIMENTAL
Intervention: Micro bur, retrograde filling and IRM
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment at apical and radicular portions
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Ultrasonic device for retrograde cavity preparation
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment at apical and radicular portions instead of micro bur
Number of subjects: 320
Study: 7625112

Group type: EXPERIMENTAL
Intervention: DTPwHBV vaccine administered in three doses (2 months apart)
Number of subjects: 42
Study: 2152973

Group type: EXPERIMENTAL
Intervention: High-fiber oat bran (87 g per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fiber refined wheat
Number of subjects: 20
Study: 647185

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 28
Study: 31740429

Group type: EXPERIMENTAL
Intervention: Home-based family-based weight loss treatment
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard of care family-based weight loss treatment delivered in an academic medical center
Number of subjects: 266
Study: 28949281

Group type: EXPERIMENTAL
Intervention: Activity-based mirror therapy (MT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional management (Control)
Number of subjects: 36
Study: 28605294

Group type: EXPERIMENTAL
Intervention: CryJ2-LAMP DNA vaccine (4 doses of 4mg/1ml for non-sensitive subjects and 4 doses of 2mg/0.5ml for sensitive subjects)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CryJ2-LAMP DNA vaccine (1 booster dose of 2mg/0.5ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CryJ2-LAMP DNA vaccine
Number of subjects: 24
Study: 25214645

Group type: COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Standard Behavioral Treatment + Enhanced Parenting (SBT + EP)
Number of subjects: 38
Study: 24601050

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg for 10 days during a month for three months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 45
Study: 21390898

Group type: EXPERIMENTAL
Intervention: Self-administered computerized version of TOMM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Examiner-administered booklet version of TOMM
Number of subjects: 0
Study: 19624323

Group type: EXPERIMENTAL
Intervention: Immediate assessment group (completed questionnaires at baseline, 3, 6, and 12 months)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Immediate assessment group
Number of subjects: 147

Group type: COMPARATOR
Intervention: Delayed assessment group (completed questionnaires only at 12 months)
Number of subjects: 147
Study: 17606952

Group type: EXPERIMENTAL
Intervention: Provider intervention sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: No provider intervention sessions (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patient intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (patients of providers who did not attend intervention)
Number of subjects: 100
Study: 15860094

Group type: EXPERIMENTAL
Intervention: Guidelines with training workshop and educational outreach visit
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study: 12398427

Group type: EXPERIMENTAL
Intervention: Low spasticity SCI subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High spasticity SCI subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderately spastic SCI subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study: 10604885

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8959681

Group type: EXPERIMENTAL
Intervention: Tallimustine 750 micrograms/m2 intravenously every 4 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tallimustine
Number of subjects: 14
Study: 1683301

Group type: EXPERIMENTAL
Intervention: 0.75 mg levonorgestrel tablets (two types)
Number of subjects: 361
Study: 7241391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sodium 2,3‐dimercaptopropane‐1‐sulfonate
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Thiolated resin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: D‐penicillamine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: N‐acetyl‐DL‐penicillamine
Number of subjects: 63
Study: 29254421

Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SPT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Active control group of cognitive stimulation
Number of subjects: 49
Study: 27939188

Group type: EXPERIMENTAL
Intervention: Standard‐length CWMT (45‐min/session, 25 sessions)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Shortened‐length CWMT (15-min/session, 25 sessions)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 135
Study: 25749644

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 14171
Study: 23603450

Group type: EXPERIMENTAL
Intervention: High Perseverance of Effort subscale
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High Consistency of Interest subscale
Number of subjects: 40
Study: 21797102

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 100
Study: 20017943

Group type: EXPERIMENTAL
Intervention: Daivobet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: calcipotriol
Number of subjects: 24

Group type: COMPARATOR
Intervention: betamethasone
Number of subjects: 24
Study: 18074501

Group type: EXPERIMENTAL
Intervention: liposuction plus diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: diet‐only
Number of subjects: 12
Study: 15069173

Group type: EXPERIMENTAL
Intervention: Low-calcium dialysate (LCD; calcium: 1.25 mmol/l)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard calcium dialysate (SCD; calcium: 1.75 mmol/l)
Number of subjects: 44
Study: 11750653

Group type: EXPERIMENTAL
Intervention: Cor a 1.0401
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cor a 1.0402
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cor a 1.0403
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cor a 1.0404
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: rCor a 1.0401
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: rCor a 1.0402
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: rCor a 1.0403
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: rCor a 1.0404
Number of subjects: 43

Group type: COMPARATOR
Intervention: Native hazelnut extract
Number of subjects: 43
Study: 11038831

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study: 7939388

Group type: EXPERIMENTAL
Intervention: NOVA ISE for IMg2+
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KONE ISE for IMg2+
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospitalized patients (randomly selected)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with coronary heart disease, rectal cancer, and multiple sclerosis
Number of subjects: 0
Study: 2526993

Group type: EXPERIMENTAL
Intervention: High dose omega-3 fatty acid (N3FA) supplementation (4.5 g/day)
Number of subjects: 194

Group type: COMPARATOR
Intervention: No N3FA (control)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: N3FA supplementation (4.5 g/day)
Number of subjects: 194
Study: 848927

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 31634905

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (4 g; n=415)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Cryoprecipitate (10 units; n=412)
Number of subjects: 735
Study: 28736559

Group type: EXPERIMENTAL
Intervention: Levocarnitine injections (1,000 mg 3 times weekly after hemodialysis)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levocarnitine injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 60
Study: 26371709

Group type: EXPERIMENTAL
Intervention: M2 haplotype carriers
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (fertile couples)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Patients with RSA (live birth vs no live birth)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Patients with RSA (positive vs negative for known risk factors)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Male and female partners in each group
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: M2 haplotype carriers with other risk factors
Number of subjects: 500
Study: 23851972

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) as an adjunct to usual care
Number of subjects: 469
Study: 21275916

Group type: EXPERIMENTAL
Intervention: IGFBP-1 in cervical secretion with expectant management
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Bishop score with expectant management
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Cervical length with expectant management
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: IGFBP-1 in cervical secretion with induction of labor
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Bishop score with induction of labor
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Cervical length with induction of labor
Number of subjects: 508
Study: 20007408

Group type: EXPERIMENTAL
Intervention: S. repens (Saw palmetto)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: P. africanum (African plum tree)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic blocking drug
Number of subjects: 3300
Study: 16411993

Group type: EXPERIMENTAL
Intervention: Kneeling position
Number of subjects: 271

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 271
Study: 15630469

Group type: EXPERIMENTAL
Intervention: three successive fixed therapy interruptions (TIs) of 2, 4, and 6 weeks, with intervening resumption of therapy for 4 weeks before subsequent interruption
Number of subjects: 42

Group type: COMPARATOR
Intervention: 40 weeks of continuous therapy
Number of subjects: 42
Study: 11264969

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 9222086

Group type: EXPERIMENTAL
Intervention: ET-1 (0 (saline), 1.25, 2.5 and 5.0 ng/kg/min; 20 minutes per dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8490471

Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 184

Group type: COMPARATOR
Intervention: Mild exercise
Number of subjects: 184
Study: 3819261

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine mesylate (DEM, Hydergine) at 6 mg per day, administered orally for 12 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31728731

Group type: EXPERIMENTAL
Intervention: Desensitizing agents (Vertise Flow, Universal Dentin Sealant, Clearfil Protect Bond, Flor‐Opal Varnish)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 40
Study: 28448426

Group type: EXPERIMENTAL
Intervention: Filorexant 10 mg nightly
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 27989253

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (60 ml dose)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24048913

Group type: COMPARATOR
Intervention: Normal training group (G1) - maintained the same training program (8-repetitions × 4-sets with 4-min recovery)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tapering group (G2) - performed reduced training volume (3 sets/exercise; -22%)
Number of subjects: 20
Study: 23737453

Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg once daily for 10 days with warfarin 25 mg on day 5
Number of subjects: 14

Group type: COMPARATOR
Intervention: Warfarin 25 mg on day 1
Number of subjects: 14
Study: 20502393

Group type: EXPERIMENTAL
Intervention: Patient-delivered partner treatment (PDPT) with metronidazole
Number of subjects: 252
Study: 18443798

Group type: EXPERIMENTAL
Intervention: Early detection and treatment of amblyopia; specific intervention details not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective randomized controlled studies; specific intervention details not available.
Number of subjects: 0
Study: 16636989

Group type: EXPERIMENTAL
Intervention: Fermented product containing Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard yogurt (control)
Number of subjects: 0
Study: 12819517

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for nelfinavir
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (no TDM) for nelfinavir
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for indinavir
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (no TDM) for indinavir
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for both drugs
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (no TDM) for both drugs
Number of subjects: 147
Study: 12135821

Group type: EXPERIMENTAL
Intervention: Multifactorial home visit programme consisting of five home visits by a community nurse over a period of 1 year
Number of subjects: 0
Study: 10099058

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily (clinical dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 200 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 600 mg (200 mg three times daily)
Number of subjects: 0
Study: 8030631

Group type: EXPERIMENTAL
Intervention: Various statistical methods for intervention studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from a school-based smoking cessation trial
Number of subjects: 0
Study: 3057847

Group type: EXPERIMENTAL
Intervention: Routine and emergency transtelephonic follow‐up and ECG monitoring
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Lidocaine injections
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Outpatient post‐myocardial infarction transtelephonic surveillance program
Number of subjects: 1004
Study: 31423939

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 25725366

Group type: EXPERIMENTAL
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Posterolateral Fusion (PLF)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control Group (Healthy Volunteers)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both PLIF and PLF
Number of subjects: 99
Study: 23043681

Group type: EXPERIMENTAL
Intervention: Predischarge TSB screening
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Combined clinical risk factors and age-adjusted TSB
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Combined screening (clinical risk factors + TSB)
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: TcB/TSB combined with GA alone
Number of subjects: 1157
Study: 21753062

Group type: EXPERIMENTAL
Intervention: iTFA
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CLA
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (oleic acid)
Number of subjects: 61
Study: 19137363

Group type: EXPERIMENTAL
Intervention: Fast-track treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 17117182

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV 6/11/16/18 L1 virus-like particle vaccine
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study: 16929590

Group type: EXPERIMENTAL
Intervention: Silybum marianum 160 mg orally three times a week for four weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: No-treatment (control)
Number of subjects: 34
Study: 11336929

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy (6 mg per square meter of body surface area) administered by intravenous infusion over 10 minutes, followed by laser treatment at 689 nm.
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo therapy (5% dextrose in water) administered by intravenous infusion over 10 minutes, followed by sham laser treatment.
Number of subjects: 339
Study: 9153366

Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate adhesive
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 130